Introduction: Progressive multifocal leukoencephalopathy (PML) is a rare demyelinating brain infection caused by JC polyomavirus (JCV), primarily seen in patients with severely compromised cellular immunity. Clinical presentation varies depending on the affected white matter. PML prognosis is variable and effective treatments are lacking.
Introduction
Progressive multifocal leukoencephalopathy (PML) is a rare demyelinating lytic brain infection caused by JC polyomavirus (JCV) (Hirsch et al., 2013) . Over half of the general population becomes infected with JC virus during life, causing a lifelong asymptomatic infection in various organs, including the bone marrow and kidneys (Hirsch et al., 2013) . It is only when the cellular immune system becomes severely compromised, mainly due to human immunodeficiency virus (HIV), transplantation or immune modulating monoclonal antibodies (specifically natalizumab), that JCV reactivation causes PML (Hirsch et al., 2013) . Specific mutations and genomic rearrangements found in JC DNA derived from PML brain tissue are thought to lead to viral tropism for the brain and increased virulence. At what stage JCV crosses the blood-brain barrier to infect the brain remains unclear.
PML has a subacute onset and symptoms are highly variable, depending on the affected white matter. Typical symptoms are cognitive decline, vision loss, impaired speech and paralysis. Signs of inflammation are generally absent (Hirsch et al., 2013) . Asymptomatic PML has been described in multiple sclerosis (MS) patients (Wattjes et al., 2015) . In general, prognosis of PML is poor depending on the capability of restoring the host immune system (Hirsch et al., 2013) .
In this report, we present a unique case of a patient who developed symptomatic PML months after discontinuation of her rather mild immunosuppressive therapy.
Case report
A 75-year-old Chinese woman with type 2 diabetes mellitus, chronic kidney disease and rheumatoid arthritis received treatment for a rare Pleurostomophora richardsiae infection of her left arm. This 'black fungus' was cultured from two separate sterile pus cultures and one wound culture of the left arm and sent to the CBS Fungal Biodiversity Centre and Radboud University Medical Centre for determination. She developed this fungal infection after using methotrexate (7.5 mg weekly) and prednisolone (7.5 mg daily) for 2.5 years. After 6 months of voriconazole, repeated surgical eradication and immunosuppression discontinuation, she presented with fatigue and light-headedness. A week later, she was admitted with progressive weakness, paresis of her right arm and fluctuating apathy. Physical examination demonstrated afebrile encephalopathy with right-sided hemiparesis. A brain magnetic resonance imaging (MRI) was made and a lumbar puncture was performed. Acyclovir was started empirically.
Investigations
Laboratory results showed normal electrolytes, unaltered renal function (creatinine 181 umol l À1 ), C-reactive protein 7.1 mg l À1 and leucocyte count 9.4*10E9 l À1 , with normal differentiation. There were no signs of hepatic failure. Brain MRI revealed white matter lesions in both frontal lobes affecting the deep and juxtacortical white matter (Fig. 1) . The lesions showed spreading along the white matter tract entering the contralateral hemisphere via the genu anterius of the corpus callosum. A lumbar puncture showed no pleiocytosis (1*106 l À1 leucocytes with no erythrocytes) and only minimally elevated protein (0.51 g l À1 ) and normal glucose (4.7 mmol l À1 ) levels in the cerebrospinal fluid (CSF). HIV, syphilis, borreliosis and toxoplasmosis were ruled out serologically. CSF tested negative by PCR for human herpes viruses and enteroviruses while positive for JCV establishing the diagnosis of PML. Retrospectively performed PCRs on two consecutive blood samples taken 2 months before PML diagnosis were negative for JCV. A urine sample taken 2 weeks after diagnosis showed shedding of JCV in the urine. Peripheral lymphocyte counts were always normal, except during the period of active and still untreated black fungus infection, when they were marginally depressed to levels between 0.46 and 0.75*109 l À1 (Fig. 2 ). CD4 and CD8 T-cell counts at PML diagnosis were 454 mm À3 and 277 mm
À3
, respectively, whereas the absolute peripheral B-cell count was only 8 mm À3 (with normal total IgG, IgM and IgA levels). CD8 T-cells, isolated at PML diagnosis, reacted to JCV VP1 peptide stimulation with TNFa secretion (Fig. 3) . For this assay, a JCV VP1 peptide pool (PepTivator ® ) was purchased from Miltenyi Biotec and used according to the manufacturer's instructions. In brief, thawed peripheral blood mononuclear cell (PBMC) was either rested for 2 h and incubated with 1 µg ml À1 brefeldin A for additional 4 h or stimulated for 6 h with 20 µl of PepTivator ® stock solution for 5Â106 PBMC/ml, as well as addition of 1 µg ml À1 brefeldin A after 2 h. Harvested cells were then stained with fluorochrome-conjugated antibodies against CD3, CD4, CD8 and CD56; fixated and permeabilized and intracellularly stained with a fluorochrome-conjugated antibody against TNFa (Biolegend) as previously described (Breuer et al., 2014) .
Diagnosis
There was a PML due to JC virus reactivation in rheumatoid arthritis patients with severe immunodeficiency.
Treatment
Mirtazapine was started to block glial cell infection through the serotonin receptor 5HT2a (Hirsch et al., 2013) and, 4 weeks thereafter (when permission for off-label use was received), Maraviroc, a CCR5 antagonist used in HIV, was initiated (Giacomini et al., 2014) .
Outcome and follow-up
Unfortunately, our patient quickly deteriorated due to PML progression, which led to her death 5 weeks after diagnosis and treatment initiation.
Discussion PML is a rare demyelinating lytic brain infection caused by JCV (Hirsch et al., 2013) . Over half of the general population becomes infected with JC virus during life, causing a lifelong asymptomatic infection, unless the immune system is severely compromised due to AIDS, transplantation or immune modulating monoclonal antibodies, specifically natalizumab (Hirsch et al., 2013) . Asymptomatic PML has been described in MS patients (Wattjes et al., 2015) . Only few PML cases have been reported with rheumatoid arthritis (Palazzo & Yahia, 2012) . Symptoms have a subacute onset and are highly variable, depending on the affected white matter. Typical symptoms are cognitive decline, vision loss, impaired speech and paralysis. Signs of inflammation are generally absent (Hirsch et al., 2013) .
In retrospect, the persistent black fungus infection in our patient was a hallmark of severely compromised cellular immunity. Surprisingly, peripheral lymphocyte counts were never extremely low and both CD4 and CD8 T-cell counts at PML diagnosis were (close to) normal. In addition, CD8 T-cells secreted TNFa after stimulation with a JCV VP1 peptide pool. This strongly indicates the presence of JCV-specific lymphocytes, which can be found in the majority of healthy individuals (Du Pasquier et al., 2004; Koralnik et al., 2001) . The only striking result was an exceptionally low absolute B-cell count (8 mm À3 ). Although the role of B-cell depletion in PML pathogenesis is unknown, the increased PML risk in rituximab-treated patients suggests a protective role for B-cells. The paradoxical clinical onset of PML months after immunosuppressives discontinuation and relatively high CD4 count suggests that PML was only discovered in the context of an immune reconstitution inflammatory syndrome (IRIS) (Palazzo & Yahia, 2012) , as seen in HIV patients on antiretroviral therapy and in MS patients after natalizumab discontinuation (Palazzo & Yahia, 2012) . Only few PML cases have been reported with rheumatoid arthritis (Palazzo & Yahia 2012) . Most cases were treated with rituximab and methotrexate and ), U+=positive JCV PCR on urine (8 log2 copies ml
À1
).
had peripheral lymphopenia. Yet, PML without severe lymphocytopenia has been sparsely reported (Nieuwkamp et al., 2015; Dammeier et al., 2015; Hoepner et al., 2015) . Up until now, there has been no specific successful treatment for PML. The most important goal of treatment is to restore immune control over JCV replication by discontinuing immunosuppressives or, in case of HIV, starting antiretroviral therapy. Routine use of corticosteroid therapy in PML IRIS is not recommended, as it may inhibit immune recovery and therefore lead to disease progression (Hirsch et al., 2013) . Our patient was treated with Mirtazapine to block glial cell infection via the 5HT2a receptor, which has been used with variable success in several studies (Hirsch et al., 2013) . In view of the relatively high levels of (activated) CD4 and CD8 T-cell counts, permission for off-label Maraviroc prescription, a CCR5 antagonist used as antiretroviral agent in HIV-infected patients, was requested (Giacomini et al., 2014) . Previously, our group successfully treated three HIV-negative PML patients under the hypothesis that lowering CD4 T-cell activation increases its antiviral function (Middel et al., 2015) . Unfortunately, our patient died due to PML progression after only 1 week of Maraviroc therapy (Giacomini et al., 2014) .
This case report demonstrates that even patients on relatively mild immunosuppressive drugs and no measured severe lymphopenia may have a compromised cellular immunity and therefore are at risk of developing PML. Moreover, in these patients, PML may develop clinically silent, only becoming symptomatic when immune reconstitution has started. 
